Prostate Cancer (PC) is a disease predominately of the elderly with 60% of cases diagnosed in men aged 65 or over. Prostate cancer is slow growing, and asymptomatic at its earliest stages. However, with the use of digital rectal examination, the PSA test, and the incidental discovery of tumors following resection of the prostate, the majority of PC cases are diagnosed at an early stage (60%).

Pune, India -- (SBWire) -- 10/18/2016 --Global revenues for the PC market are forecast to rise at a moderate CAGR of 9.5% from $7.6bn in 2014 to $13.6bn in 2021.

Prostate Cancer (PC) is a disease predominately of the elderly with 60% of cases diagnosed in men aged 65 or over. Prostate cancer is slow growing, and asymptomatic at its earliest stages. However, with the use of digital rectal examination, the PSA test, and the incidental discovery of tumors following resection of the prostate, the majority of PC cases are diagnosed at an early stage (60%).

Browse more detail information about Prostate Cancer Market: http://www.absolutereports.com/prostate-cancer-market-to-2021-increasing-disease-prevalence-to-be-a-key-driver-of-market-growth-10070563

As PC is slow growing, many patients can leave their disease untreated for extended periods of time with frequent monitoring (watchful waiting or active surveillance), with many patients dying from other causes before treatment is indicated. Surgery and/or radiotherapy is often curative when treatment is indicated for localized disease, with androgen deprivation being the standard of first-line care.

Get a PDF Sample of Prostate Cancer Market to 2021: http://www.absolutereports.com/enquiry/request-sample/10070563

Scope of Prostate Cancer Market to 2021:

Global revenues for the PC market are forecast to rise at a moderate CAGR of 9.5% from $7.6bn in 2014 to $13.6bn in 2021.

- What factors are driving the market growth?
- How can the factors limiting growth be overcome in the future?

The pipeline addresses clinical need in the market; seven of the nine late-stage pipeline products are being developed as therapies for metastatic castration resistant disease.

- What other gaps in the market are being addressed by the current pipeline dynamics?

The variation in molecule type has shifted away from small molecules (predominately hormonal therapies), the dominance of which has decreased from 91% across marketed products to 50% across the pipeline.

- What are the dynamics of the remaining 50% of the pipeline?
- How does this reflect the need for novel targeted therapies?

There has been a significant shift away from hormonal therapies. Key mechanisms of action across the pipeline include cancer immunotherapies against PSMA, whole cell vaccines and targeted therapies against the PI3K/Akt/mTOR pathway.

- What is the scientific rationale behind these targets?
- How successful have drugs against these targets been? How successful are they expected to be in the future?

Several drugs are expected to be approved during the forecast period: ProstAtak, ODM201, ARN-509, and Tookad. However, their sales are expected to be limited by high costs and a lack of comparative trials.

- Where will these novel therapies fit into the current treatment algorithm for PC?

Have any query? ask our expert @ http://www.absolutereports.com/enquiry/pre-order-enquiry/10070563

Reasons to buy Prostate Cancer Market to 2021:

This report will allow you to -

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis.

- Visualize the composition of the PC market in terms of dominant molecule types and targets, highlighting the current unmet needs and how they can be addressed to allow a competitive understanding of gaps in the current market.

- Analyze the PC pipeline and stratify by stage of development, molecule type, and molecular target.

- Visualize the clinical safety and efficacy of late-stage pipeline drugs via a detailed heat map, outlining the results across major clinical trial endpoints.

- Understand the growth in patient epidemiology, annual therapy costs, and market revenues for the AML market globally and across the US, UK, France, Germany, Italy, Spain, Japan, and Canada.

- Identify commercial opportunities in the PC deals landscape by analyzing trends in licensing and co-development deals.

Get Discount on Prostate Cancer Market to 2021: http://www.absolutereports.com/enquiry/request-discount/10070563

List of Figures, Tables and Charts Available in Prostate Cancer Market to 2021 - Increasing Disease Prevalence to be a Key Driver of Market Growth

1.1 List of Tables
Table 1: Prostate Cancer Therapeutics, Commonly Mutated or Overexpressed Genes 12
Table 2: Prostate Cancer Therapeutics, Disease Stage Classification 15
Table 3: Prostate Cancer Therapeutics, Risk Classification for Localized Cancer, D'Amico System 16
Table 4: Prostate Cancer Therapeutics, Common Definitions of High-Risk Prostate Cancer 16
Table 5: Marketed GnRH Agonists and Their Routes of Administration for Prostate Cancer 21
Table 6: Prostate Cancer Therapeutics, Top Five European Markets, Forecast Growth in Prevalence and Treatment Populations, 2014–2021 90
Table 7: Prostate Cancer Therapeutics, Top Five European Markets, Annual Cost of Therapy ($), 2014–2021 92
Table 8: Prostate Cancer Therapeutics, Top Five European Markets, Market Size ($m), 2014–2021 94
Table 9: Prostate Cancer Therapeutics, Global, Developmental Pipeline, Discovery, 2015 111
Table 10: Prostate Cancer Therapeutics, Global, Developmental Pipeline, Preclinical, 2015 115
Table 11: Prostate Cancer Therapeutics, Global, Developmental Pipeline, IND/CTA-Filed, 2015 129
Table 12: Prostate Cancer Therapeutics, Global, Developmental Pipeline, Phase I, 2015 130

No of Pages: 164
Single User Price: USD 4995
Purchase report at: http://www.absolutereports.com/purchase/10070563

List of Exhibits

1.1 List of Tables
Table 1: Prostate Cancer Therapeutics, Commonly Mutated or Overexpressed Genes 12
Table 2: Prostate Cancer Therapeutics, Disease Stage Classification 15
Table 3: Prostate Cancer Therapeutics, Risk Classification for Localized Cancer, D'Amico System 16
Table 4: Prostate Cancer Therapeutics, Common Definitions of High-Risk Prostate Cancer 16
Table 5: Marketed GnRH Agonists and Their Routes of Administration for Prostate Cancer 21
Table 6: Prostate Cancer Therapeutics, Top Five European Markets, Forecast Growth in Prevalence and Treatment Populations, 2014–2021 90
Table 7: Prostate Cancer Therapeutics, Top Five European Markets, Annual Cost of Therapy ($), 2014–2021 92

About Absolute Report
Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market dedicated towards bringing you an ingenious concoction of data parameters.

Contact:
Mr. Ameya Pingaley
Absolute Reports
408-520-9750
Email: sales@absolutereports.com
http://www.absolutereports.com
Get more market research related news @ http://www.marketresearch.news